GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Revvity Inc (NYSE:RVTY) » Definitions » Enterprise Value

Revvity (Revvity) Enterprise Value : $14,967 Mil (As of May. 02, 2024)


View and export this data going back to 1983. Start your Free Trial

What is Revvity Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Revvity's Enterprise Value is $14,967 Mil. Revvity's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $289 Mil. Therefore, Revvity's EV-to-EBIT ratio for today is 51.87.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Revvity's Enterprise Value is $14,967 Mil. Revvity's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $719 Mil. Therefore, Revvity's EV-to-EBITDA ratio for today is 20.81.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Revvity's Enterprise Value is $14,967 Mil. Revvity's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $2,726 Mil. Therefore, Revvity's EV-to-Revenue ratio for today is 5.49.


Revvity Enterprise Value Historical Data

The historical data trend for Revvity's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revvity Enterprise Value Chart

Revvity Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12,856.80 17,902.26 29,939.38 21,850.89 15,953.91

Revvity Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18,836.88 17,207.08 16,238.96 15,953.91 15,278.35

Competitive Comparison of Revvity's Enterprise Value

For the Diagnostics & Research subindustry, Revvity's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Revvity's Enterprise Value Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Revvity's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Revvity's Enterprise Value falls into.



Revvity Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Revvity's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Revvity's Enterprise Value for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Revvity  (NYSE:RVTY) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Revvity's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=14967.051/288.557
=51.87

Revvity's current Enterprise Value is $14,967 Mil.
Revvity's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $289 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Revvity's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=14967.051/719.12
=20.81

Revvity's current Enterprise Value is $14,967 Mil.
Revvity's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $719 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Revvity's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=14967.051/2725.626
=5.49

Revvity's current Enterprise Value is $14,967 Mil.
Revvity's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $2,726 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Revvity Enterprise Value Related Terms

Thank you for viewing the detailed overview of Revvity's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Revvity (Revvity) Business Description

Traded in Other Exchanges
Address
940 Winter Street, Waltham, MA, USA, 02451
Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.
Executives
Anita Gonzales officer: Please See Remarks 940 WINTER STREET, REVVITY, WALTHAM MA 02451-1457
Andrew Okun officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Maxwell Krakowiak officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451-1457
Daniel R Tereau officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Tajinder Vohra officer: Please See Remarks 940 WINTER STREET, WALTHAM MA 02451-1457
Prahlad R. Singh officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 024511457
Joel S Goldberg officer: See Remarks 940 WINTER STREET, WALTHAM MA 02451
Michelle Mcmurry-heath director C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM NC 27703
James M Mock officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Sylvie Gregoire director 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
Miriame Victor officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451-1457
Peter Barrett director C/O ALNYLAM PHARMACEUTICALS, INC., 300 THIRD STREET, CAMBRIDGE MA 02142
Michel Vounatsos director BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Alexis P Michas director 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
Pascale Witz director C/O REGULUS THERAPEUTICS INC., 10614 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121

Revvity (Revvity) Headlines

From GuruFocus

Q4 2021 PerkinElmer Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q3 2022 PerkinElmer Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q4 2022 PerkinElmer Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q1 2023 PerkinElmer Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024